The HERCULES study of tolebrutinib is the first and only to show reduced confirmed disability progression at 6 months in nonrelapsing secondary progressive multiple sclerosis (MS). The HERCULES ...

Results from the HERCULES phase 3 study showed delay in disability progression in people living with non-relapsing secondary progressive multiple sclerosis Tolebrutinib has the potential to be the ...

Data also showed that the number of participants who experienced confirmed disability improvement increased by around two-fold. Liver enzyme elevations were observed in 4.1% of participants receiving ...

Data presented at ECTRIMS show that tolebrutinib, a brain-penetrant BTK inhibitor, addresses disability accumulation that occurs independently from relapse activity Global regulatory submissions will ...

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application for tolebrutinib for the treatment of non-relapsing secondary progressive multiple sclerosis (nrSPMS).

Treatment with tolebrutinib delayed the time to onset of 6-month CDP by 31% compared with placebo. The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to tolebrutinib ...

In the HERCULES study, tolebrutinib met the primary endpoint in delaying time to onset of confirmed disability progression in people with nrSPMS, a population for which there are currently no approved ...

(RTTNews) - French drug major Sanofi (SNY) announced Friday that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to tolebrutinib for the treatment of adults with non ...

Please provide your email address to receive an email when new articles are posted on . No new safety signals or serious adverse events were reported. Of 124 participants who received tolebrutinib 60 ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. MRI paramagnetic rim lesions are associated with ...

Results from the HERCULES phase 3 study showed delay in disability progression in people living with non-relapsing secondary progressive multiple sclerosis Tolebrutinib has the potential to be the ...

Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study Data presented at ECTRIMS show that ...